ReviewMediators of inflammation2014
Anti-TNF-alpha therapy and systemic vasculitis.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Case Report: Acute onset hemiparesis in a young man: do not miss Crohn's disease.Frontiers in immunology · 2025Article
- Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Review
- Isolated Celiac Artery Vasculitis Presenting as Ileus in a Patient With Ulcerative Colitis.ACG case reports journal · 2024Article
- Article
- The Growing Spectrum of DADA2 Manifestations-Diagnostic and Therapeutic Challenges Revisited.Frontiers in pediatrics · 2022Article
- Incidence of Tuberculosis in Systemic Necrotizing Vasculitides: A Population-Based Study From an Intermediate-Burden Country.Frontiers in medicine · 2020Article
- Infliximab for the treatment of refractory polyarteritis nodosa.Clinical rheumatology · 2019Review
- Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol.PLoS neglected tropical diseases · 2019Article
- Characterization of Novel Fragment Antibodies Against TNF-alpha Isolated Using Phage Display Technique.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Giant cell arteritis: early diagnosis is key.Eye and brain · 2019Review
- Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab.Biologics : targets & therapy · 2019Article
- Negative effects of a high tumour necrosis factor-α concentration on human gingival mesenchymal stem cell trophism: the use of natural compounds as modulatory agents.Stem cell research & therapy · 2018Article
- Isolation and Characterization of Novel Phage Displayed scFv Fragment for Human Tumor Necrosis Factor Alpha and Molecular Docking Analysis of Their Interactions.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Biological Therapy-Induced Systemic Vasculitis.Current rheumatology reports · 2016Review
- Identification of Novel Single Chain Fragment Variable Antibodies Against TNF-α Using Phage Display Technology.Advanced pharmaceutical bulletin · 2015Article
- Production and Purification of a Novel Anti-TNF-α Single Chain Fragment Variable Antibody.Advanced pharmaceutical bulletin · 2015Article
- Impaired function of endothelial progenitor cells in children with primary systemic vasculitis.Arthritis research & therapy · 2015Article
- Etanercept induces remission of polyarteritis nodosa: a case report.Frontiers in pharmacology · 2014Article
- Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet's disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.